One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 3, 2005, Pages 360-363

  Zéphir, Helene ^a   de Seze, J ^a   Dujardin, K ^a   Dubois, G ^a   Cabaret, M ^a   Bouillaguet, S ^a   Ferriby, D ^a   Stojkovic, T ^a   Vermersch, P ^a  

^a UNIV LILLE   (France)

Author keywords

Cognitive function; Cyclophosphamide; Methylprednisolone; Progressive multiple sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; DRUG PULSE THERAPY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTELLIGENCE; INTELLIGENCE TEST; MALE; MEMORY; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; SCORING SYSTEM; VERBAL MEMORY;

ADULT; ANTI-INFLAMMATORY AGENTS; COGNITION; COGNITION DISORDERS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 20144381537     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1172sr     Document Type: Article

References (10)

1. Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology 1995; 45: 718-23.
2. Goodkin DE. Interferon beta therapy for multiple sclerosis. Lancet 1998; 352: 1486-87.
3. Weinstein A, Schwid SIL, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56: 319-24.
4. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM et al. Neuropsychological effects of Interferon β-1a in relapsing multiple sclerosis. Ann Neurol 2000; 48: 885-92.
5. Barak Y, Achiron A. Effects of interferon beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002; 47: 11-14.
6. Thompson AJ, Polman CH, Miller H, McDonald WI, Brochet B, Fillipi M et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-96.
7. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
8. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8: 142-54.
9. Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 1997; 120: 289-97.
10. Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E. Changes of the MS Functional Composite EDSS during and after treatment of relapses with methylprednisolone in patients with MS. Acta Neurol Scand 2002; 105: 164-68.